Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03211351
Other study ID # FSHX-001
Secondary ID
Status Completed
Phase N/A
First received July 5, 2017
Last updated February 22, 2018
Start date July 1, 2017
Est. completion date January 25, 2018

Study information

Verified date October 2017
Source Huaxia Eye Hospital Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With the potential to address evaporative dry eye, Liposic and Tears Naturale Forte have been developed in which phospholipid liposomes are delivered to the tear film via the surface of the closed eyelid. This study compare the effects of Liposic and Tears Naturale Forte application on the lipid and stability of the tear film in dry eye patients


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date January 25, 2018
Est. primary completion date December 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- Age range from 20 year to 40 years

- The value of OSDI is over 12

- NBUT is less 5 seconds

- Schirmer 1 test is less 10mm

- The basical lipid layer grade is 1-2

Exclusion Criteria:

- Any corneal,conjunctival, or eyelid abnormalities; conjunctivitis; current ocular infection; photophobia that may cause reflex tearing or difficulty in evaluating the patien 's lipid layer;

- Known allergic sensitivity to any of the ingredients in Liposic or Tears Naturale Forte

Study Design


Intervention

Drug:
Liposic
one eye of the participant recieved Lipoic
Tears Naturale Forte
the other eye of the participant recieved Tears Naturale Forte

Locations

Country Name City State
China Huaxia Eye Hosptial of Foshan Foshan Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Huaxia Eye Hospital Group

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary scale of Schirmer I test up to 3 months after tear substitutes apply
Primary scale of corneal fluorescein staining up to 3 months after tear substitutes apply
Primary scale of noninvasive tear breakup time up to 3 months after tear substitutes apply
Primary scale of tear meniscus height up to 3 months after tear substitutes apply
Primary lipid layer grade up to 3 months after tear substitutes apply
Primary questionnaire of ocular surface disease index up to 3 months after tear substitutes apply
Secondary subjective comfort up to 3 months after tear substitutes apply
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A